Physician profile
Vida Farhangi
NPI 1851390983
$2,054.83
in general payments reported to CMS, 2019-2025
9 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $155 · 2024: $177 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,440 · Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,440.00 |
| Food and Beverage | $614.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,564.95 | 2023-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $120.33 | 2025 | Korlym |
| Amgen INC. | $94.49 | 2025 | Evenity |
| Calliditas Therapeutics US INC. | $89.46 | 2024 | |
| Intuitive Surgical, INC. | $63.75 | 2024 | |
| Aimmune Therapeutics, INC. | $49.56 | 2025 | Vowst |
| Boston Scientific Corporation | $29.65 | 2023 | Watchman Access System |
| Exact Sciences Corporation | $23.54 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $19.10 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vida Farhangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.